Statement on Roche Announcement on Gantenerumab Attributed to John Dwyer, GAP Foundation President

The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of enormous importance as we improve on the next generation of trials and therapies for people living with Alzheimer’s.


For immediate release:

About the Global Alzheimer’s Platform Foundation (GAP)

The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites around the world through study start up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.

To top